GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (LTS:0HL9) » Definitions » Short Percentage of Float

Affimed NV (LTS:0HL9) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Affimed NV Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Affimed NV's Short Percentage of Float

For the Biotechnology subindustry, Affimed NV's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Affimed NV's Short Percentage of Float falls into.


;
;

Affimed NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (LTS:0HL9) » Definitions » Short Percentage of Float
Comparable Companies
CLDI INAB PHGE ABVC BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AFMD:USA
Address
Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Website
https://www.affimed.com
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV Headlines

No Headlines